

FOSUN PHARMA
复星医药

2023



- ①
- ②
- ③
- ④
- ⑤
- ⑥



213.95

(+ 0.22%YoY)

- HER2 () PD-1
- mRNA

+ 15%YoY

- PD-1 5.6
- HER2 57.1%
- 32.7%
- TNF-

28.84

(+ 19.77%YoY)

- 21.34 + 16.80%YoY
- + 22.16%YoY
- 15.75%
- 25.19
- 17.92
- 11.20%

17.77

(+ 15.74%YoY)

- 1H23 4.05

13.73

(- 26.28%YoY)

- Gland Pharma

18.10

(+ 0.63%YoY)



2/2



1H23

1/2

	1H23				1H23			
	1H23	5.56			1H23	57.1%		
	3	ES-SCLC		ES-SCLC	2		BLA	FDA
	3	PD-1						
	3	ES-SCLC	MAA	EMA				
	6	WHO PQ	16		1)		2 *	
						4	7	
	2			P-CAB				
		DU	RE					
	6					7	*	CKD
	5		CKD		III	HER2		3
		SHPT						
	8				4	III	2	
	6		r/r LBCL		1		2 *	/
					NF1	I		4
	1	2023	2021		7			
	1	2023	2019					




SAB

(GT1-GT6) Go/No-Go




Pre- 8 FDA





&







CAR-T



4 PDE4



2019 - 2022



PD-1



P-CAB

DU

RE





SHPT

CKD



r/r LBCL

2023 - 2024




Öğ and



API





MSCI-ESG

A

A

2023

BBB
2021

BB
2020

2023

MSCI ESG

*

A

2023

ESG

A-

A

A

2023

*

1

2023 6



E nvironment

EHS

2021-2026

EHS

EHS

2022

115.36

337,806

3.2%



S ocial

PQ

Argesun®

3

WHO

1



G overnance

ESG

ESG


10

2023 1




—


1



2,3



3



-

SCLC

PD-1



ES-SCLC



1H23

5.56



MSI-H

sqNSCLC

ES-SCLC

SCLC FDA EC

ES-SCLC

ES-SCLC

MAA

EMA

(ASTCT) r/r LBCL


				1			
2023 6 r/r LBCL				!			
CAR-T				82% 83% 83%			
				58% 58% 65%			
B LBCL LBCL NHL 45.8% NHL LBCL 4				43% 5 84% 1 55% 4			
1.3				r/r NHL 83.2% 58.4% 12 84.3%			

500				2023 6 140 25 10,000 GMP			
2023 6 60 90							

				FL MZL 2021 8 r/r FL			
Kite Pharma CAR-T Tecartus 2020 7 FDA r/r ALL				/ MCL			


1				B DLBCL DLBCL NCCN NCCN CSCO I			
2023				CSCO			

-







1



1,2



1



Sisram

Breas

/

1H23 Vivo 1 2 3

6

CT

POCT

1H23

T

PCR-

F-A7000



Series



8.99%

1
2

2023












1



2,3



3



2011-2017



2018-2020



2021



600

2017 11

9.09

1,750

2022

21.45


1.11

87.41%







()




()





1		®	2019 2 2 RA	3 RA	1	
2		®	1 HER2 Phoenix S.A. 40	2 Accord Healthcare Limited	3 PT Kalbio Global Medika Laboritorio ELEA	
3		®	Zercepac PD-1 1 CSCO	Tuzucip 2022 3 MSI-H CSCO	Trastucip PD-1 2 CSCO	
4		®	2020 12 1	GMP 2	3 4	
5		®	2020 4		ITP	

6		®	2021 8 PDE4	4	
7		®	2019 8 NK-1 5-HT3		
8		®	2023 6	1	
9		®	SOT		
10		®	2021 6 1 12 B B CAR-T r/r DLBCL r/r LBCL	2	
11		®			

12		®	2023 5 SHPT	CKD	
13		®	P-CAB 1 P-CAB 2023 2 DU RE	DU/RE	
14			Artesun SPAQ-CO 1 33 WHO PQ 2023 6 WHO PQ 16 2023 6	+ D-ARTEPP Argesun 3	
15		®	RNA 2022 7	HIV-1	
16		®	mRNA / 6 4 BNT162b2 Omicron BA.4-5 5 11 EUA		
17					

1/2

			/			IND	1	2	3	NDA
HLX10 ¹	+		PD-1	/	III 2022 11					
					2022 11 2022 FDA/EC 2023 1					
	+	+	PD-1		III 2023 1 2022 5					
	+	PD-1+VEGF								
	+HLX07	PD-1+EGFR								
	+HLX07	PD-1+EGFR +VEGF	2022 1							
	HLX07		EGFR							
	HLX22	+	+	HER2						
HLX22	+	+	HER2+ PD-1 +HER2							
HLX11	2		HER2	III 2022						
HLX05	3		EGFR							
HLX02	4		HER2	FDA 2020						

1 KG Bio 10
3
5 2023 7 31

2 Organon
4 Accord Cipla Jacobson mAbxience Eurofarma Abbott



2/2

[illegible]

1/2

		I		IND	1	2	3	NDA
FCN-437c		CDK4/6	1L					
			2L					
SAF-189		ALK/ROS1	ALK+					
			ROS1+					
HLX-208	-	BRAF	Erdheim-Chester ECD LCH					
	+	BRAF+PD-1	BRAF V600E BRAF V600					
FCN-159		MEK	I					
YP01001		VEGFR						
FCN-338		BCL-2						

2/2

		/			IND	1 g P %Z °RZ E → Ô`	3	NDA
		TPO-R	ITP					
	Tenapanor	NHE 3	(ESRD-HD)					
		P-CAB						
	Tenapanor	NHE 3	(IBS-C)					
	PA-824	-	XDR-TB / MDR-TB					
	Opicapone	COMT						
	Fortacin							

			IND	1	2	3	NDA
	/						
	/						
	/						
13							
24							
23							
	-						

FOSUN

LOGO

Fosun Pharma, the Representor or the Provider will not warrant the accuracy, the completeness and the timeliness of all information and contents, including predictive description, contained in the PPT documents/visual materials. In the event of any mistake, omission, and inaccuracy, Fosun Pharma, the Representor or the Provider should not be held for any liabilities in this regard.

The PPT documents/visual materials will not include and should not be deemed as any investment proposals. The investor should take their own responsibilities for any determinations so come to based upon the information contained in the PPT documents/visual materials.

Fosun Pharma is entitled to all rights, including copyright, pertaining to the PPT documents/visual materials. The characters, the designs and other related logos, like Fosun and , are the trade name, trademark and the logos legally owned by Fosun Pharma. Without written consent offered by Fosun Pharma, any third party should not utilize such materials and information in any manner, including reprinting.

FOSUN PHARMA



www.fosunpharma.com